The eye condition, known as non-arteritic anterior ischemic optic neuropathy, can cause significant vision loss and has been reported with all GLP-1 drugs. FDA adds rare vision-loss warning to GLP-1 obesity/diabetes drugs like Ozempic and Wegovy, urging prompt medical attention for optic symptoms. The FDA said GLP-1 drugmakers must add labels warning of NAION, a rare condition that can lead to decreased vision and blindness.